Introduction
Because of their high sensitivity, positron emission tomography (PET) studies for imaging of neuroendocrine tumors have recently raised interest (1) (2) (3) (4) (5) (6) (7) . To visualize these tumors, the principle of amine precursor uptake and decarboxylation (8) and imaging of the somatostatin receptor plays a major role. Neuroendocrine tumors possess the unique property of synthesis, storage, and secretion of biogenic amines. Clinically applied tracers to visualize this are 6-[ The first factor is the fact, as both tracers are amino acids, that they may well be a substrate for transmembrane amino acid transporters. The Na + -independent transporters large amino acid transporter (LAT)-1, LAT2, LAT3, and LAT4 are defined as system L transporters and can be blocked by the model substrate amino-2-norbornanecarboxylic acid (BCH; ref. 9) . LAT transporters are responsible for the transport of large neutral amino acids across the cellular membrane.
Second, the precise effects of the peripheral decarboxylation inhibitor carbidopa, generally given to patients before [ 11 C]HTP or [ 18 F] FDOPA tracer injection to improve uptake, are poorly understood.
A third factor involved can be monoamine oxidase (MAO). It plays a major role in the metabolism of tryptophan and L-DOPA and is the enzyme responsible for the degradation of serotonin (5-HT) to 5-hydroxyindole acetic acid (5-HIAA) and of dopamine to homovanillic acid. Based on inhibitor sensitivity and substrate selectivity, MAOs are subtyped as MAO A and B (10, 11) . Whereas MAO A is mainly responsible for the degradation of 5-HT, MAO B breaks down both 5-HT and dopamine (12) . With the use of selective and nonselective MAO inhibitors like clorgyline (MAO A) and pargyline (MAO A and B), the effect of the MAOs on tracer trapping can be examined (13, 14) . An increased accumulation due to reduced intracellular metabolism of [ The aim of the present study was the analysis of the uptake of [ 11 C]HTP and [ 18 F]FDOPA by LAT, peripheral decarboxylation by amino acid decarboxylase (AADC), and intracellular breakdown by MAO in vitro. Finally, experiments with carbidopa were extended to a tumor-bearing animal model to get a better understanding of the in vivo metabolism using microPET.
Materials and Methods
Tracers. Synthesis of [ 18 F]FDOPA was carried out as described earlier (15) with an average specific activity of 9.8 GBq/mmol after end of synthesis. The tracer was diluted with 0.9% saline to the required concentration of f100 nmol/mL. [ 18 F ]FDOPA at 0.19 F 0.01 mL, corresponding to a dose of 6.17 F 0.63 MBq, was injected per animal. [ 11 C]HTP was synthesized via an enzymatic method with an average specific activity of 30,000 GBq/mmol after end of synthesis as recently described (16) . It was used at a concentration of f0.67 nmol/mL. [
11 C]HTP at 0.24 F 0.02 mL, corresponding to a dose of 10.79 F 1.18 MBq, was injected per animal.
Chemicals. 5-HTP, 5-HT, 5-HIAA, carbidopa, clorgyline, pargyline hydrochloride, and BCH were purchased from Sigma. GMC (5.6 mmol/L D-glucose, 0.49 mmol/L MgCl 2 , 0.68 mmol/L CaCl 2 ) was added to PBS solution (140 mmol/L NaCl, 2.7 mmol/L KCl, 6.4 mmol/L Na 2 HPO 4 , 0.2 mmol/L KH 2 PO 4 ). The pH of the resulting PBS-GMC solutions was adjusted to 7.4 with sodium hydroxide. PBS-GMC was used to deplete internal amino acid pools (17, 18) . Matrigel was purchased from BD Biosciences.
Cell culture. Experiments were done with the human neuroendocrine pancreatic tumor cell line BON (19) . Cells were maintained in 25-cm 2 culture flasks in 5-mL DMEM/F-12 (1:1) medium supplemented with 10% FCS containing the amino acids L-phenylalanine (215 Amol) and L-tryptophan (44 Amol) among others. Cells were grown in a humidified atmosphere containing 5% CO 2 and were routinely subcultured every 3 to 4 d. Cultures grown to a cell density of 1.0 Â 10 6 to 1.4 Â 10 6 cells/mL were used for the experiments.
Cells were harvested by trypsin treatment, resuspended, and diluted 3:7 in culture medium on 12-well plates 1 d before the experiments (1 mL/well). The viability and number of cells were determined by the trypan blue exclusion technique. Cell viability 1 to 2 h after experiments was >90%.
At the day of experiment, cells were washed with warm PBS (3 Â 2 mL) and 1 mL of culture medium or PBS-GMC buffer was added per well. The cells were then placed in a water bath for 1 h at 37jC before start of the experiments to allow depletion of internal amino acids. Accumulation experiments were started by addition of 150-AL [ 18 Inhibition experiments. Various concentrations of the blocking agent BCH (0-20 mmol/L) were applied to determine an adequate blocking concentration. To maintain cell viability, carbidopa was used at a maximum concentration of 0.08 mmol/L because higher concentrations of carbidopa induced apoptosis. Clorgyline and pargyline were added at a concentration of 0.1 mmol/L (20, 21) . Inhibition experiments were carried out by adding 1 mL of culture medium (control and carbidopa only) or PBS-GMC containing the blocking agent in the relevant concentration to each well. Afterward, cells were incubated for 1 h to achieve the required amino acid depletion. Subsequently, tracer incubation was done and intracellular accumulation determined as described above. A tracer incubation time of 15 min was used for the blocking agent BCH. Tracer incubation times ranging from 5 to 60 min with AADC and MAO inhibitors carbidopa, clorgyline, and pargyline were used. Due to the short half-life of 11 C, incubation periods longer than 60 min were not applied.
Nonlabeled tracer accumulation. Because of the short half-life of PET isotopes, the detection and quantification of radioactive 5-HTP metabolites like 5-HT or 5-HIAA is limited. A sensitive automatic detection method of 5-HTP and its metabolites used in carcinoid patients was used for the detection of nonlabeled tracer in vitro (22) . For these experiments, culture medium was removed from the 25-cm 2 culture flasks. Cells were then washed with PBS (3 Â 2 mL). Five milliliters of PBS-GMC buffer containing the carbidopa (0.08 mmol/L), the MAO A inhibitor clorgyline (0.1 mmol/L), or the nonselective MAO inhibitor pargyline (0.1 mmol/L) were added. After the 1-h depletion period, non-radioactive-labeled 5-HTP (55 nmol/L) was added in 5-mL PBS-GMC buffer.
After 15 and 60 min of tracer incubation, PBS-GMC buffer was removed. The buffer supernatant was analyzed for the amounts of 5-HIAA. Preconcentration was done by liquid-liquid extraction in the following way. Per sample, 2 drops of glacial acetic acid, 1 g of NaCl, and 5 mL of diethyl ether were added and slightly shaken. After centrifugation at 2,000 Â g for 5 min, the organic phase was transferred into a test tube and diethyl ether evaporated in a slight stream of nitrogen. Samples were dissolved in eluent and analyzed as described earlier (22) .
For the analysis of 5-HTP metabolites, supernatant was removed and the cells were harvested with 1-mL trypsin and resuspended in 1-mL PBS containing 10% FCS. Cells were washed thrice with ice-cold PBS (1 mL) and centrifuged for 10 min at 10,000 Â g. Cells were lysed using liquid nitrogen. The concentrations of 5-HTP, 5-HT, and 5-HIAA present in the lysed BON cells dissolved in 1-mL saline were determined by the method described above. Cellular accumulation of nonlabeled tracer was defined as the amount of substance detected in lysed cells divided by the total amount of 5-HTP in incubation medium at the start of the experiment. All results were represented as the mean of three experiments (FSE).
Animals. Nude male mice (BALB/c, age 6-8 wk, body weight 18-24 g) were obtained from Harlan Netherlands BV. Experimental groups consisted of four to five animals to perform microPET scanning after injection of [ 11 C]HTP and [ 18 F] FDOPA. The total number of studied animals was 36. Animals were housed in temperature-and humidity-controlled rooms with 12-h day and 12-h night cycles and were provided with forage and water ad libitum. Animals were housed in HEPA-filtered cages in the animal research facility of the University Medical Center Groningen under controlled water, lab chow, humidity, and temperature conditions. At least 2 h before starting the experiments, the animals were acclimated to laboratory conditions. All animal experiments were done by licensed investigators in compliance with the Law on Animal Experiments of the Netherlands. The study protocol was approved by the Committee on Animal Ethics of the University of Groningen.
MicroPET scanning. Sixty-minute dynamic scanning followed by 10-min transmission scanning was done using a Concorde microPET Focus 220 system equipped with microPET manager for data acquisition in list mode and ASIPro for preparing sinograms and image reconstruction. Using ASIPro's clipping tool, areas with very high activity that were not relevant to the current study, such as the liver region, were removed as to yield a more cleaned up version of the scan that is, therefore, easier to evaluate. Ordered subset expectation maximization (OSEM2D) statistics was applied for the quantitative analysis. The PET acquisition data were fully corrected for dead time, random coincidences, attenuation, and scatter. PET image size was 128 Â 128 Â 95 voxels. In 
Statistics. Differences between various groups were tested for statistical significance using Student's t test for independent samples. P < 0.05 was considered significant. (Fig. 2) . The lowest used concentration of 0.03 mmol/L BCH resulted in a reduction of tracer accumulation to 45% compared with control for [ 18 F] FDOPA and a BCH IC 50 value of 0.01 mmol/L. Nonlabeled tracer accumulation. In BON cells (control), apart from 5-HTP, both 5-HT and 5-HIAA were detected 15 and 60 minutes after starting incubation. Only low cellular 5-HT levels (0.6 F 0.1% after 60 minutes) were found compared with 5-HTP (12.0 F 0.0% after 60 minutes) and 5-HIAA (11.9 F 0.8% after 60 minutes) levels. Treatment with carbidopa neither increased 5-HTP (3.0 F 0.9% after 60 minutes) nor decreased the cellular levels of 5-HT (3.0 F 0.3% after 60 minutes) or 5-HIAA (11.8 F 1.4% after 60 minutes). Clorgyline, however, increased 5-HT (18.4 F 2.9% after 60 minutes) and decreased 5-HIAA levels (0.9 F 0.0% after 60 minutes). Similar results were obtained after pargyline treatment (5-HT, 29.3 F 5.0%; 5-HIAA, 2.4 F 0.2% after 60 minutes; Fig. 3) .
Results
Animal experiments. Thirty-six mice were divided into eight groups of four to five animals (control and carbidopa) and given [ 18 Fig. 4 ). Within 5 minutes after i.v. tracer injection, the plateau phase of the Biodistribution data after scanning showed high SUVs for liver, kidney, and pancreas for both tracers (i.v.). SUVs were not significantly altered after carbidopa treatment compared with control (Fig. 5) . Although tumor SUVs in microPET images were higher for [ 18 
F]FDOPA, [
11 C]HTP resulted in higher uptake in most organs; significant differences in uptake were noted for spleen, RBC, and blood plasma irrespective of carbidopa treatment.
Discussion
Cellular accumulation of [ (24, 25) . The retention of neurotransmitters is considered to be the result of uptake (LAT), decarboxylation (AADC), and granular storage by vesicular monoamine transporters (VMAT). The latter process prevents enzymatic breakdown in the cytoplasm (MAO) and subsequent secretion. One of the most important factors of VMAT activity is the amount of 5-HT or catecholamines in secretory vesicles (26, 27) . In our cell studies, the medium was free of amino acids and metabolites, tentatively resulting in reduced filling of secretory granules. This theoretically led to higher VMAT-substrate activity. Separate granular storage of 5-HT and catecholamines may explain the differences in retention for [ 11 (36) . In nude mice bearing a BON tumor, carbidopa increased tracer tumor accumulation within the tumor, resulting in better imaging (Fig. 6) . Our mouse PET images show high accumulation in the abdominal region. This is in line with our mice biodistribution data of high SUVs for organs such as liver and kidney located in this region. In the tumor model that we used, which was derived from a human pancreatic tumor cell line, [ 18 
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